US4867978A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of prolonging cancerous patient survival in humans with hydrazine sulfate
Assignee: Individual
•
Filing: 1988-11-25
•
Granted: 1989-09-19
•
Expires: 2008-11-25
Abstract
Abstract Hydrazine sulfate, alone or formulated with liquid or solid carriers, will prolong patient survival when administered to early-stage human cancer patients parenterally or orally.
Inventors
- 👤 Joseph Gold
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:32
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/04; A61K33/02
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
50 words
A method for prolonging patient survival in an early-stage human cancer patient which comprises internally administering to said human hydrazine sulfate in an effective dosage sufficient in amount and for a duration of from fourteen weeks to four years to prolong patient survival without treating a cancerous tumor per se.
Claim 2
Independent Claim
50 words
A method for prolonging patient survival in an early-stage human cancer patient which comprises internally administering to said human hydrazine sulfate in an effective dosage sufficient in amount and for a duration of from fourteen weeks to four years to prolong patient survival without treating a cancerous tumor per se.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the hydrazine sulfate is administered orally in dosage form.
Claim 4
Dependent Claim
15 words
The method of claim 2 wherein the dosage form is a gelatin capsule or tablet.
Claim 5
Dependent Claim
12 words
The method of claim 1 wherein the hydrazine sulfate is administered parenterally.
Claim 6
Dependent Claim
20 words
The method of claim 1 wherein the dosage of hydrazine sulfate is 1 to 5 mg/kg of body weight daily.
Claim 7
Dependent Claim
46 words
The method of claim 1 wherein the hydrazine sulfate is administered in a daily regimen of one 60 milligram capsule for three days, then two 60 milligram capsules for the next three days, and three 60 milligram capsules each day thereafter for up to four years.
Claim 8
Dependent Claim
55 words
The method of claim 1 wherein the hydrazine sulfate is administered to patients weighing less than 100 pounds in a daily regimen of one 30 milligram capsule for three days, then two 30 milligram capsules for the next three days, then two or three 30 milligram capsules each day thereafter for up to four years.
References Cited (Backward Citations)
US4110437A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-18 | 1993-03-20 | 1993-09-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-18 | 1997-03-20 | 1997-09-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-18 | 2001-03-20 | 2001-09-19 | $7700.00 | Window Closed / Lapsed |